|
Re-jigging the matrix with Third Eye's involvement
|
8
|
Resverlogix Corp.
|
Apr 11, 2018 05:55PM
|
|
Re: "Actively Recruiting" ?
|
1
|
Resverlogix Corp.
|
Nov 04, 2021 02:03PM
|
|
Re: "Actively Recruiting" ?
|
4
|
Resverlogix Corp.
|
Nov 04, 2021 02:16PM
|
|
Re: "Actively Recruiting" ?
|
3
|
Resverlogix Corp.
|
Nov 04, 2021 02:48PM
|
|
Re: "Do we actually have a Breakthrough Therapy Designation?"
|
4
|
Resverlogix Corp.
|
Jun 14, 2023 03:37PM
|
|
Re: "So if you get fantastic results in a Brazilian COVID-19 clinical trial, be prepared..." is my read.
|
2
|
Resverlogix Corp.
|
Jul 30, 2021 05:18PM
|
|
Re: "So if you get fantastic results in a Brazilian COVID-19 clinical trial, be prepared..." is my read.
|
3
|
Resverlogix Corp.
|
Jul 28, 2021 08:54PM
|
|
Re: "So if you get fantastic results in a Brazilian COVID-19 clinical trial, be prepared..." is my read.
|
5
|
Resverlogix Corp.
|
Aug 01, 2021 02:07PM
|
|
Re: "top line data on or before January 31, 2019" A Covenant of the loan
|
3
|
Resverlogix Corp.
|
Dec 19, 2018 08:44PM
|
|
Re: "we are in now in the hands of the PI's running the trials"
|
1
|
Resverlogix Corp.
|
Oct 21, 2021 05:13PM
|
|
Re: "We have the vaccine, but we shouldn’t be resting on our laurels...."
|
8
|
Resverlogix Corp.
|
Jul 21, 2021 06:17PM
|
|
Re: "We have the vaccine, but we shouldn’t be resting on our laurels...."
|
6
|
Resverlogix Corp.
|
Jul 22, 2021 02:25AM
|
|
Re: # Of Sites
|
|
Resverlogix Corp.
|
Jun 05, 2019 03:28PM
|
|
Re: (Newsfile Corp. - July 16, 2024)
|
1
|
Resverlogix Corp.
|
Jul 16, 2024 10:41AM
|
|
Re: ,Hong Kong exchange
|
2
|
Zenith Epigenetics
|
Apr 27, 2018 12:09PM
|
|
Re: ,Hong Kong exchange
|
1
|
Zenith Epigenetics
|
Apr 27, 2018 12:16PM
|
|
Re: ,Hong Kong exchange
|
3
|
Zenith Epigenetics
|
May 01, 2018 04:54AM
|
|
Re: ... a question
|
2
|
Resverlogix Corp.
|
May 04, 2018 03:09PM
|
|
Re: ... and now we wait...
|
5
|
Resverlogix Corp.
|
Dec 14, 2017 12:21AM
|
|
Re: ... BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE...
|
5
|
Resverlogix Corp.
|
Apr 25, 2018 04:14PM
|
